ADMA Biologics (ADMA) Misses Q4 EPS by 11c

ADMA Biologics (NASDAQ: ADMA) reported Q4 EPS of ($0.08), $0.11 worse than the analyst estimate of $0.03. Revenue for the quarter came in at $73.9 million versus the consensus estimate of $72.15 million.

For earnings history and earnings-related data on ADMA Biologics (ADMA) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• JPMorgan Upgrades YDUQS Participacoes SA (YDUQ3:BZ) to Overweight
• Morgan Stanley Downgrades Sands China Ltd. (1928:HK) (SCHYY) to Equalweight